Cargando…

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

PURPOSE: Recently, the British Myeloma Research Alliance put forward a Myeloma Risk Profile (MRP) for the first time to stratify the prognosis risk of non-transplanted patients with multiple myeloma. However, only limited studies have evaluated the applicability of this model in the Chinese populati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Kewa, Ye, Jiannan, Wang, Lingling, Sun, Chao, Zhou, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039846/ https://www.ncbi.nlm.nih.gov/pubmed/33854333 http://dx.doi.org/10.2147/OTT.S300834

Ejemplares similares

Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
por: Fan, Liping, et al.
Publicado: (2017)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
por: Bove, Virginia, et al.
Publicado: (2021)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
por: Côté, Julie, et al.
Publicado: (2023)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
por: Pulte, Elizabeth Dianne, et al.
Publicado: (2018)

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
por: Luoma, Sini, et al.
Publicado: (2019)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis
por: Lin, Chi-Maw, et al.
Publicado: (2023)

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients
por: Hu, Ying, et al.
Publicado: (2019)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

P1274: IMPACT OF AUTOLOGOUS TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL TRIPLETS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Amitai, Irina, et al.
Publicado: (2023)

P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
por: Pasvolsky, Oren, et al.
Publicado: (2023)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study: Treatment pattern and outcomes in patients with multiple myeloma
por: He, Jianming, et al.
Publicado: (2020)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cfhdbfiphm11p3cmj2lp5p40n1